Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Nbi
BIOPLASMA FDP lyophilised powder for IV infusion REGISTRATION NUMBER 28/30.3/405 PROPRIETARY NAME (and dosage form): BIOPLASMA FDP lyophilised powder for IV infusion DESCRIPTIVE NAME OF MEDICINE Fresh Human Plasma PHARMACOLOGICAL CLASSIFICATION A 30.3 Biologicals (Blood fractions) SCHEDULING STATUS S4 COMPOSITION Bioplasma FDP is produced from pooled fresh human plasma of volunteer, non-remunerated blood donors. Each unit of plasma has been individually tested and found non-reactive for hepatitis B surface antigen, antibodies to the hepatitis C virus and antibodies to the human immunodeficiency viruses, HIV-1 and HIV-2, using approved methods. Bioplasma FDP is prepared using a solvent-detergent treatment process, which inactivates lipoprotein-coated viruses including HIV, hepatitis B and hepatitis C. After reconstitution with Water for Injection each 100 mL Bioplasma FDP contains 4 g - 6 g plasma proteins with a normal distribution of human plasma components including albumin, immunoglobulins, coagulation and complement factors and their inhibitors. Bioplasma FDP contains a minimum of 0,4 IU/mL of each coagulation factor.QuickMarkQuickMark Bioplasma FDP contains no antimicrobial agent or preservative. IDENTIFICATION Lyophilised powder: light-yellow to yellow powder or solid friable mass. Reconstituted solution: slightly opalescent solution. PHARMACOLOGICAL ACTION OF THE MEDICINE Plasma and coagulation factor replacement. INDICATIONS Bioplasma FDP can be used where plasma and/or coagulation factors are required. CONTRA-INDICATIONS Known hypersensitivity to plasma proteins, including patients with IgA deficiency. The risk of hypersensitive reactions should be weighed against that of the condition. Bioplasma FDP must not be used for volume replacement where no coagulation disorder is present. The safety Read the complete document